MedTrace Logo

Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab

NCT02963402 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2018-11-14

No results posted yet for this study

Summary

We can speculate that the best responders to tocilizumab should have multiple related elements (Treg CD39, adenosine, IL-35) successfully induced and expressed in order to play its beneficial role. The study of these elements and its pathways could help identify the best responders to tocilizumab treatment.

Conditions

  • Arthritis,Rheumatoid

Interventions

DRUG

Tocilizumab

DRUG

Adalimumab

Sponsors & Collaborators

  • Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-09
Primary Completion
2018-10-01
Completion
2018-10-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02963402 on ClinicalTrials.gov